What is William Blair's Estimate for NTLA Q2 Earnings?

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Analysts at William Blair issued their Q2 2026 earnings per share (EPS) estimates for Intellia Therapeutics in a research note issued on Wednesday, March 26th. William Blair analyst M. Minter forecasts that the company will post earnings of ($1.22) per share for the quarter. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.07) per share.

Other equities analysts have also recently issued reports about the stock. Truist Financial reduced their price target on shares of Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Morgan Stanley cut Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their target price for the company from $56.00 to $11.00 in a research note on Monday, January 27th. Barclays dropped their price target on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Citigroup boosted their price objective on Intellia Therapeutics from $12.00 to $14.00 and gave the company a "neutral" rating in a research report on Friday, February 28th. Finally, HC Wainwright assumed coverage on shares of Intellia Therapeutics in a report on Wednesday, March 5th. They set a "buy" rating and a $30.00 target price on the stock. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $37.56.

Remove Ads

Intellia Therapeutics Stock Down 5.0 %

Intellia Therapeutics stock traded down $0.36 during midday trading on Friday, hitting $6.76. 2,463,762 shares of the stock were exchanged, compared to its average volume of 2,209,507. The stock has a market capitalization of $699.26 million, a PE ratio of -1.24 and a beta of 1.97. The company has a fifty day simple moving average of $9.93 and a two-hundred day simple moving average of $13.63. Intellia Therapeutics has a 52 week low of $6.71 and a 52 week high of $28.18.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Capstone Investment Advisors LLC lifted its holdings in Intellia Therapeutics by 1.4% during the 3rd quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company's stock valued at $1,256,000 after purchasing an additional 831 shares during the last quarter. Ensign Peak Advisors Inc lifted its stake in shares of Intellia Therapeutics by 2.9% during the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company's stock worth $457,000 after buying an additional 1,100 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Intellia Therapeutics by 10.3% during the 3rd quarter. Franklin Resources Inc. now owns 16,405 shares of the company's stock worth $320,000 after buying an additional 1,538 shares during the period. Allspring Global Investments Holdings LLC grew its stake in Intellia Therapeutics by 14.0% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company's stock valued at $157,000 after buying an additional 1,582 shares during the last quarter. Finally, Arizona State Retirement System raised its holdings in Intellia Therapeutics by 6.1% in the 4th quarter. Arizona State Retirement System now owns 28,006 shares of the company's stock valued at $327,000 after acquiring an additional 1,615 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the business's stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now owns 941,115 shares of the company's stock, valued at $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last three months, insiders have sold 29,000 shares of company stock valued at $352,551. 3.20% of the stock is currently owned by corporate insiders.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.